摘要
目的 观察度拉糖肽联合益生菌对2 型糖尿病患者糖脂代谢、胰岛功能和心血管事件的影响,提高对治疗安全性的重视.方法 选取2022 年1 月至2024 年1 月收治的120 例2 型糖尿病患者,根据治疗方式的不同分为观察组和对照组各60 例,对照组给予基础治疗联合度拉糖肽治疗,观察组在对照组基础上加用双歧杆菌四联活菌片治疗,均连续治疗3 个月.比较2 组治疗后空腹血糖、糖化血红蛋白、餐后 2h血糖水平和体质量指数,2 组治疗前后空腹胰岛素、胰岛β细胞功能指数(HOMA-β)水平和胰岛素抵抗指数(HOMA-IR),统计 2 组治疗期间心血管事件发生情况,以及2 组治疗后C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)水平.结果 治疗后观察组空腹血糖、餐后2h血糖、糖化血红蛋白和体质量指数低于对照组(P＜0.05).治疗后2 组HOMA-β、空腹胰岛素升高,HOMA-IR降低(P＜0.05);治疗后观察组HOMA-β高于对照组,HOMA-IR低于对照组(P＜0.05).治疗期间观察组心血管事件总发生率低于对照组(P＜0.05).治疗后,观察组IL-6、TNF-α、CRP及总胆固醇、三酰甘油、LDL-C均低于对照组(P＜0.05).结论 度拉糖肽联合益生菌治疗可以有效稳定2 型糖尿病患者血糖及血脂水平,改善胰岛功能和控制体质量,同时还能减轻炎症反应,进而大幅度降低心血管不良事件的发生率,提高药物应用安全性.
Abstract
Objective To observe the effects of duolatopeptide combined with probiotics on glucose and lipid metabo-lism,islet function and cardiovascular events in patients with type 2 diabetic mellitus(T2DM),in order to increase the atten-tion to treatment safety.Methods A total of 120 T2DM patients treated from January 2022 to January 2024 were selected and divided into the observation group(n=60)and the control group(n=60)according to different treatment methods.The con-trol group was given basic treatment combined with Duloglucopeptide therapy,and the observation group was treated with bifidobacterium tetrad viable tablet on the basis of the control group.Both groups were treated for three consecutive months.Fasting blood glucose(FBG),glycated hemoglobin(HbA1c),2 h postprandial blood glucose(2 h PBG)levels and body mass index(BMI)of the two groups after treatment,fasting insulin,islet beta cell function index(HOMA-β)levels and in-sulin resistance index(HOMA-IR)of the two groups before and after treatment were compared,and cardiovascular events of the two groups during treatment were analyzed.In addition,the levels of C reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),total cholesterol(TC),triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)after treatment in the two groups were compared.Results After treatment,FBG,2 h PBG,HbA1c and BMI in ob-servation group were lower than those in control group(P＜0.05).After treatment,HOMA-β and fasting insulin were in-creased,while fasting HOMA-IR was decreased in the two groups than those before treatment(P＜0.05).After treatment,HOMA-β was higher while HOMA-IR was lower in observation group than in control group(P＜0.05).The total incidence of cardiovascular events in the observation group was lower than that in the control group(P＜0.05).After treatment,IL-6,TNF-α,CRP,TC,TG and LDL-C in observation group were lower than those in control group(P＜0.05).Conclusion Duo-laglycopeptide combined with probiotics can effectively stabilize blood glucose and lipid levels in T2DM patients,improve islet function,control body mass,and reduce inflammatory reaction,thus greatly reducing the incidence of cardiovascular adverse events and improving the safety of drug use.
国家科技期刊平台
NSTL
万方数据